^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

bleomycin

Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor
Related drugs:
2d
Fatty acid synthesis therapy-induced senescence (FASTIS) in cancer cells. (PubMed, Cell Death Dis)
mRNA sequencing reveals an FASTIS-associated transcriptomic profile that overlaps between ACC and FASN inhibitors yet differs significantly from that of other mechanistically diverse TIS inducers, including bleomycin, alisertib, doxorubicin, and palbociclib. The FASTIS phenomenon is a therapeutic outcome through which cancer cells adapt to survive clinical-grade lipogenesis inhibitors. The cholesterol-addicted FASTIS fate can be rationally exploited as a collateral sensitivity in "one-two punch" senogenic-(immuno)senolytic strategies.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • BCL2L1 (BCL2-like 1)
|
Ibrance (palbociclib) • doxorubicin hydrochloride • alisertib (MLN8237) • bleomycin
9d
Ameliorative effect of Nano berberine in bleomycin- induced lung fibrosis in male rats. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Furthermore, Nano-Brb reduced transforming growth factor-beta 1 (TGF-β1) expression and upregulated pulmonary sirtuin 3 (SIRT3) gene expression. The present results suggest that Nano-Brb enhanced the lung's architecture and functional performance by modulating inflammatory cytokines, oxidative stress, gene expression, and histopathological damage.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TGFB1 (Transforming Growth Factor Beta 1) • SIRT3 (Sirtuin 3) • IL13 (Interleukin 13) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • CTGF (Connective tissue growth factor)
|
bleomycin
25d
The effects of Salmonella enterica cell extract on the gene expression of bleomycin hydrolase, puromycin-sensitive aminopeptidase, and thimet oligopeptidase in human colorectal adenocarcinoma cells. (PubMed, Iran J Microbiol)
enterica cell extract significantly and selectively alters the expression of TOP, a critical cytosolic peptidase involved in the final stages of antigen processing. This targeted modulation likely serves as a mechanism for immune evasion by facilitating the destruction of immunogenic epitopes, thereby rendering infected cells less visible to the adaptive immune system.
Journal
|
CD8 (cluster of differentiation 8) • BLMH (Bleomycin Hydrolase) • KLK3 (Kallikrein-related peptidase 3)
|
bleomycin
25d
Refractory Ulcerated Infantile Hemangioma Successfully Treated With Bleomycin Sclerotherapy: A Case Report. (PubMed, Am J Case Rep)
Sirolimus was initiated but clinical deterioration continued within days, leading to the decision to provide interventional management. CONCLUSIONS Bleomycin sclerotherapy may be an effective and safe therapeutic option for propranolol resistance ulcerated infantile hemangiomas that fail conventional medical therapy. Early multidisciplinary evaluation and timely escalation to interventional treatment may help prevent progressive tissue destruction and improve functional and cosmetic outcomes in selected refractory cases.
Journal
|
SLC2A1 (Solute Carrier Family 2 Member 1)
|
sirolimus • bleomycin
1m
Rapidly progressive Hodgkin lymphoma causing superior vena cava syndrome in late pregnancy: a case report and literature review. (PubMed, Front Med (Lausanne))
Postpartum positron emission tomography/computed tomography demonstrated extensive supradiaphragmatic disease, and chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine was promptly initiated. The patient showed a favorable clinical and metabolic response, and the neonate demonstrated normal early postnatal development. This case highlights the importance of early recognition and multidisciplinary management of superior vena cava syndrome in pregnancy and raises the hypothesis that pregnancy-associated immunologic changes, including interleukin-6-mediated pathways, may contribute to accelerated disease progression.
Journal
|
IL6 (Interleukin 6)
|
doxorubicin hydrochloride • dacarbazine • bleomycin • vinblastine
1m
ECT-DESMO: Electrochemotherapy for Desmoid Tumors (clinicaltrials.gov)
P=N/A, N=0, Withdrawn, Istituto Ortopedico Rizzoli | N=30 --> 0 | Trial completion date: Aug 2029 --> Aug 2025 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2028 --> Aug 2025
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
|
bleomycin
1m
New P2 trial
|
bleomycin
1m
Positron Emission Tomography imaging of tumor necrosis factor in lung injury. (PubMed, Ups J Med Sci)
This study aimed to evaluate the novel Affibody molecule-based positron emission tomography (PET) tracer [68Ga]Z0185, targeting TNF, for its ability to detect inflammation in vivo using the bleomycin (BLM)-induced lung injury model in rats...[68Ga]Z0185 bound to recombinant human TNF in vitro with a mechanism that could be partially inhibited by etanercept (131.8 ± 12.0 vs. 74.2 ± 5.6 fmol, P < 0.05)...&lsqb;68Ga]Z0185 enables non-invasive detection of localized TNF-driven inflammation in the lung. This approach offers a promising imaging tool for patient stratification, therapy monitoring, and guiding anti-TNF interventions in pulmonary diseases.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD68 (CD68 Molecule)
|
bleomycin
2ms
Giant testicular seminoma with atypical painful presentation and delayed diagnosis: a case report. (PubMed, J Surg Case Rep)
Post-operatively, tumour markers declined significantly, and the patient was commenced on bleomycin, etoposide, and cisplatin chemotherapy. This case emphasizes that painful scrotal swelling does not exclude malignancy and highlights the importance of early recognition and multidisciplinary management.
Journal
|
AFP (Alpha-fetoprotein)
|
cisplatin • etoposide IV • bleomycin
2ms
Enrollment change
|
Keytruda (pembrolizumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • dacarbazine • bleomycin • vinblastine
2ms
Knockout of Mucin 1 inhibits the proliferation, migration, and invasion of human MDA-MB-231 cells by blocking autophagy flow. (PubMed, Braz J Med Biol Res)
Autophagy flow was assessed by western blot and Ad-mCherry-GFP-LC3B dual-fluorescence system and validated by lysosome inhibitor barfimycin A1 and autophagy inducer rapamycin...Compared with the control group, MUC1 knockout led to a significant increase of autophagy-related proteins LC3-II and p62, which is consistent with the effect of lysosome inhibitor bleomycin A1...The expression level of LAMP1 was downregulated and the lysosome pH increased, but the expression levels of STXl7 and SNAP29 were not affected. These findings suggest that MUC1 promotes malignant behaviors in MDA-MB-231 cells by regulating autophagic flow, likely through lysosomal dysfunction-mediated autophagy blockade.
Journal
|
MUC1 (Mucin 1) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
sirolimus • bleomycin
2ms
Differential Roles of BRCA1 and BRCA2 in the DNA Damage Response Revealed by isogenic V79 Mutant Cell lines. (PubMed, Mutagenesis)
B1-21 cells were particularly sensitive to camptothecin and the PARP inhibitor NU1025, whereas V-C8 cells showed higher sensitivity to etoposide, cisplatin, mitomycin C, and bleomycin. These findings indicate that partial disruption of the BRCA1 RING domain results in a hypomorphic phenotype with impaired homologous recombination, defective checkpoint control, and enhanced genotoxic sensitivity. The isogenic BRCA1 and BRCA2 mutant V79 lines offer a valuable model for dissecting DDR pathway differences and developing mutation-specific therapeutic strategies targeting BRCA-mutant cancers.
Preclinical • Journal • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • RAD51 (RAD51 Homolog A) • FANCD2 (FA Complementation Group D2)
|
BRCA2 mutation • BRCA1 mutation • BRCA mutation
|
cisplatin • etoposide IV • mitomycin • bleomycin